

Hair loss and balding: Lilac Corp Discusses New Guidelines for Treatment and Recommends Nolopecia

Lilac Corp reviews the latest guidelines for hair loss and balding treatments, and recommends Nolopecia, a natural treatment for stimulating hair growth.

SARASOTA, FL, UNITED STATES, June 14, 2018 /EINPresswire.com/ -- A new set of guidelines for the treatment of [hair loss](#) were published [1]. According to the guidelines, Rogaine (Minoxidil) and Propecia (Finasteride), are still the only two FDA approved treatments for male and female hair loss. Although approved by the FDA, these medications have known side effects. Rogaine can cause itching and redness. Propecia can cause sexual dysfunction in men, and birth defects in the babies of pregnant women taking it. In general, Propecia is not recommended for women. Newer treatments include self-hair transplantation, laser or LED irradiation, and Ketoconazole. In self-hair transplantation, the doctor transplants the patient's own natural hair taken from certain parts of the body onto the scalp. This is in contrast to artificial hair transplants, where synthetic hair fibers are used. Artificial hair transplants have been mostly banned by the FDA on the grounds of being unsafe and ineffective. [1].

“

The new treatment targets the latent viruses in the body. This helps the body maintain a normal level of the 5alpha-R, DHT, and AR proteins. A normal level of these proteins stimulates hair growth.”

Lilac Corp



All natural hair loss supplement sold by Lilac Corp

Although, nearly 400,000 patients had self-hair transplantation worldwide in 2015 [2], the new guidelines only recommend self-hair transplantation after Rogaine or Propecia were proven to be ineffective. The guidelines also say that irradiation using LED or lasers are moderately effective for hair regrowth, and have side effects that include dryness, itching, tenderness, and a tingling sensation on the scalp. Finally, according to the guidelines, Ketoconazole has only weak evidence for its effectiveness in [hair growth](#).

For men and women, who suffer from hair loss and balding, Lilac Corp recommends the natural treatment [Nolopecia](#). The new treatment targets the latent

viruses in the body. This helps the body maintain a normal level of the 5alpha-R, DHT, and AR proteins. A normal level of these proteins stimulates hair growth. There are many treatments for hair loss on the market. However, only Nolopecia targets the latent viruses that cause the increase in 5alpha-R, DHT, and AR observed in people with hair loss and balding.

Lilac Corp is the company that invented the highly effective and unique antiviral natural treatments Gene-Eden-VIR and Novirin. For more information on these products, see lilaccorp.com, or search Google. The search will produce the

clinical studies that tested the treatments and showed the safety and effectiveness of the treatments.



About Lilac Corp:

Lilac Corp specializes in the development of biology-based patent protected natural treatments. Currently, Lilac Corp is selling four products: Gene-Eden-VIR, Novirin, Nolopecia, and Noacnin. Lilac Corp ships its products to more than 100 countries around the world. What makes Lilac Corp special is that all its products are tested in clinical studies that follow FDA guidelines. To ensure transparency, the results of the clinical studies are published in leading scientific journals. Lilac Corp also offers a 90-day money back guarantee.

Sources:

[1] Manabe, M., Tsuboi, R., Itami, S., Osada, S., Amoh, Y., & Ito, T. et al. (2018). Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. The Journal Of Dermatology. doi: 10.1111/1346-8138.14470

[2] International Society of Hair Restoration Surgery (ISHRS). 2015 Practice Census: Extrapolated Number of Hair Restoration Procedures Worldwide.

John Evans
Lilac Corp
585-250-9999
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.